Our data demonstrated that OE-Smyd3 activates MEK/ERK signaling (Fig. 6g), and it was reported that the protein level of SMYD3 is sensitive to the combination treatment of trametinib (Tra, which inhibits MEK1 and MEK2) and navitoclax in PDX (patient-derived xenografts) for non-small cell lung cancer [63]. This evidence concerns the gene MAP2K2 and non-small cell lung carcinoma.